---
created: '2026-02-13T19:04:39.023148Z'
description: A procedure to collect cerebrospinal fluid (CSF) for analysis of neurodegeneration
  biomarkers including amyloid-beta, tau proteins, and emerging markers. Essential
  for ATN classification and dementia diagnosis.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/examination/lumbar-puncture/
slug: lumbar-puncture
tags:
- examination
- procedure
- csf
- biomarkers
- diagnostic
templateEngineOverride: njk
title: Lumbar Puncture
type: examination
updated: '2026-02-13T19:04:39.023148Z'
---

{% raw %}
<h1>Lumbar Puncture</h1>
<h2>Overview</h2>
<p>Lumbar puncture (LP), also known as spinal tap, is a procedure to collect cerebrospinal fluid (CSF) from the subarachnoid space. In the context of neurodegeneration, CSF analysis provides direct measurement of brain-derived biomarkers that reflect Alzheimer's pathology (Aβ42, p-tau, t-tau) and neurodegeneration (NfL, GFAP). CSF biomarkers are a cost-effective alternative to amyloid and tau PET imaging.</p>
<h2>Procedure</h2>
<h3>Technique</h3>
<ol>
<li><strong>Position</strong>: Lateral decubitus (fetal) or sitting</li>
<li><strong>Landmark</strong>: L3-L4 or L4-L5 interspace (below conus medullaris)</li>
<li><strong>Needle</strong>: 20-22 gauge atraumatic needle (Sprotte, Whitacre)</li>
<li><strong>Collection</strong>: Opening pressure, then sequential tubes</li>
</ol>
<h3>Sample Collection for Biomarkers</h3>
<table>
<thead>
<tr>
<th>Tube</th>
<th>Volume</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1-2 mL</td>
<td>Cell count, protein, glucose</td>
</tr>
<tr>
<td>2</td>
<td>1-2 mL</td>
<td>Microbiology (if indicated)</td>
</tr>
<tr>
<td>3-4</td>
<td>10-15 mL</td>
<td>AD biomarkers (polypropylene tubes!)</td>
</tr>
</tbody>
</table>
<h3>Critical Pre-analytical Factors</h3>
<ul>
<li><strong>Tube material</strong>: Polypropylene (Aβ42 adsorbs to polystyrene)</li>
<li><strong>Processing time</strong>: Process within 1-2 hours or freeze</li>
<li><strong>Centrifugation</strong>: 2000g x 10 min at 4°C</li>
<li><strong>Storage</strong>: -80°C for long-term</li>
<li><strong>Freeze-thaw cycles</strong>: Minimize (affects some analytes)</li>
</ul>
<h2>CSF Biomarkers for Neurodegeneration</h2>
<h3>Core AD Biomarkers (ATN)</h3>
<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Reflects</th>
<th>Typical Cutoff</th>
<th>Change in AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aβ42</td>
<td>Amyloid pathology</td>
<td>&lt;500 pg/mL</td>
<td>Decreased</td>
</tr>
<tr>
<td>Aβ42/Aβ40</td>
<td>Amyloid (ratio)</td>
<td>&lt;0.089</td>
<td>Decreased</td>
</tr>
<tr>
<td>p-tau181</td>
<td>Tau pathology</td>
<td>&gt;60 pg/mL</td>
<td>Increased</td>
</tr>
<tr>
<td>p-tau217</td>
<td>Tau pathology</td>
<td>Assay-specific</td>
<td>Increased</td>
</tr>
<tr>
<td>t-tau</td>
<td>Neurodegeneration</td>
<td>&gt;400 pg/mL</td>
<td>Increased</td>
</tr>
</tbody>
</table>
<h3>Additional Biomarkers</h3>
<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Reflects</th>
<th>Clinical Utility</th>
</tr>
</thead>
<tbody>
<tr>
<td>NfL</td>
<td>Axonal damage</td>
<td>Pan-neurodegeneration; prognosis</td>
</tr>
<tr>
<td>GFAP</td>
<td>Astrocyte activation</td>
<td>Neuroinflammation</td>
</tr>
<tr>
<td>Neurogranin</td>
<td>Synaptic dysfunction</td>
<td>Synaptic biomarker</td>
</tr>
<tr>
<td>sTREM2</td>
<td>Microglial activation</td>
<td>Neuroinflammation</td>
</tr>
<tr>
<td>YKL-40</td>
<td>Inflammation</td>
<td>Glial marker</td>
</tr>
<tr>
<td>α-synuclein</td>
<td>Synucleinopathy</td>
<td>PD/DLB research</td>
</tr>
</tbody>
</table>
<h2>Clinical Applications</h2>
<h3>Dementia Diagnosis</h3>
<ul>
<li>Differentiate AD from non-AD dementias</li>
<li>Confirm AD pathology in atypical presentations</li>
<li>Support clinical diagnosis in uncertain cases</li>
</ul>
<h3>ATN Classification</h3>
<ul>
<li><strong>A+</strong>: Low Aβ42 or Aβ42/40 ratio</li>
<li><strong>T+</strong>: Elevated p-tau</li>
<li><strong>N+</strong>: Elevated t-tau or NfL</li>
</ul>
<h3>Anti-Amyloid Therapy Eligibility</h3>
<ul>
<li>CSF Aβ42/40 ratio as alternative to amyloid PET</li>
<li>More accessible and less expensive</li>
<li>~90% concordance with PET</li>
</ul>
<h3>Research Applications</h3>
<ul>
<li>Longitudinal biomarker tracking</li>
<li>Clinical trial inclusion/outcome</li>
<li>Novel biomarker discovery</li>
</ul>
<h2>Contraindications and Risks</h2>
<h3>Absolute Contraindications</h3>
<ul>
<li>Skin infection at puncture site</li>
<li>Significantly raised intracranial pressure with mass effect</li>
<li>Severe coagulopathy (uncontrolled)</li>
</ul>
<h3>Relative Contraindications</h3>
<ul>
<li>Anticoagulation (may need to hold)</li>
<li>Thrombocytopenia (&lt;50,000)</li>
<li>Spinal abnormalities</li>
</ul>
<h3>Complications</h3>
<table>
<thead>
<tr>
<th>Complication</th>
<th>Incidence</th>
<th>Prevention/Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-LP headache</td>
<td>5-30%</td>
<td>Atraumatic needle, hydration</td>
</tr>
<tr>
<td>Back pain</td>
<td>10-20%</td>
<td>Proper technique</td>
</tr>
<tr>
<td>Bleeding</td>
<td>Rare</td>
<td>Correct coagulopathy</td>
</tr>
<tr>
<td>Infection</td>
<td>Very rare</td>
<td>Sterile technique</td>
</tr>
<tr>
<td>Nerve root irritation</td>
<td>Rare</td>
<td>Proper needle placement</td>
</tr>
</tbody>
</table>
<h3>Reducing Post-LP Headache</h3>
<ul>
<li>Use atraumatic (pencil-point) needles</li>
<li>Smaller gauge (22G vs 20G)</li>
<li>Replace stylet before withdrawal</li>
<li>Lie flat post-procedure (debated)</li>
<li>Hydration encouraged</li>
</ul>
<h2>Comparison: CSF vs Plasma Biomarkers</h2>
<table>
<thead>
<tr>
<th>Feature</th>
<th>CSF</th>
<th>Plasma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invasiveness</td>
<td>Lumbar puncture</td>
<td>Blood draw</td>
</tr>
<tr>
<td>Brain proximity</td>
<td>Direct</td>
<td>Indirect</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>Higher</td>
<td>Lower</td>
</tr>
<tr>
<td>Aβ42/40</td>
<td>Well-established</td>
<td>Emerging</td>
</tr>
<tr>
<td>p-tau</td>
<td>Well-established</td>
<td>Validated (p-tau217)</td>
</tr>
<tr>
<td>Availability</td>
<td>Specialty centers</td>
<td>Broader</td>
</tr>
<tr>
<td>Cost</td>
<td>Moderate (~$500-800)</td>
<td>Lower (~$200-400)</td>
</tr>
</tbody>
</table>
<h2>Relationships</h2>
<h3>Biomarkers Measured</h3>
<ul>
<li>→ <a href="/garden/dev_admin/biomarker/amyloid-beta-4240-ratio/" class="internal-link">Amyloid-Beta 42/40 Ratio</a> (biomarker) - <em>CSF gold standard</em></li>
<li>→ <a href="/garden/dev_admin/biomarker/phospho-tau/" class="internal-link">Phospho-Tau</a> (biomarker) - <em>Tau pathology</em></li>
<li>→ <a href="/garden/dev_admin/biomarker/total-tau/" class="internal-link">Total Tau</a> (biomarker) - <em>Neurodegeneration</em></li>
<li>→ <a href="/garden/dev_admin/biomarker/neurofilament-light-chain/" class="internal-link">Neurofilament Light Chain</a> (biomarker) - <em>Axonal damage</em></li>
<li>→ <a href="/garden/dev_admin/biomarker/gfap/" class="internal-link">GFAP</a> (biomarker) - <em>Astrocyte marker</em></li>
</ul>
<h3>Conditions</h3>
<ul>
<li>→ <a href="/garden/dev_admin/condition/alzheimers-disease/" class="internal-link">Alzheimer's Disease</a> (condition) - <em>Core diagnostic</em></li>
<li>→ <a href="/garden/dev_admin/condition/mild-cognitive-impairment/" class="internal-link">Mild Cognitive Impairment</a> (condition) - <em>Risk stratification</em></li>
<li>→ <a href="/garden/dev_admin/condition/creutzfeldt-jakob-disease/" class="internal-link">Creutzfeldt-Jakob Disease</a> (condition) - <em>RT-QuIC, 14-3-3</em></li>
<li>→ <a href="/garden/dev_admin/condition/multiple-sclerosis/" class="internal-link">Multiple Sclerosis</a> (condition) - <em>Oligoclonal bands</em></li>
<li>→ <a href="/garden/dev_admin/condition/normal-pressure-hydrocephalus/" class="internal-link">Normal Pressure Hydrocephalus</a> (condition) - <em>Therapeutic tap</em></li>
</ul>
<h3>Related Examinations</h3>
<ul>
<li>← <a href="/garden/dev_admin/examination/amyloid-pet-imaging/" class="internal-link">Amyloid PET Imaging</a> (examination) - <em>Alternative for A+</em></li>
<li>← <a href="/garden/dev_admin/examination/tau-pet-imaging/" class="internal-link">Tau PET Imaging</a> (examination) - <em>Alternative for T+</em></li>
</ul>
<h2>Practical Workflow</h2>
<h3>Pre-Procedure</h3>
<ol>
<li>Review indications and contraindications</li>
<li>Check coagulation if on anticoagulants</li>
<li>Consent (explain risks, benefits)</li>
<li>Prepare polypropylene tubes in advance</li>
</ol>
<h3>Procedure Day</h3>
<ol>
<li>Position patient comfortably</li>
<li>Sterile prep and drape</li>
<li>Local anesthesia</li>
<li>Atraumatic needle insertion</li>
<li>Measure opening pressure (if indicated)</li>
<li>Collect 10-15 mL in sequential tubes</li>
<li>Remove needle with stylet in place</li>
</ol>
<h3>Post-Procedure</h3>
<ol>
<li>Patient lies flat 30-60 min (optional)</li>
<li>Encourage oral hydration</li>
<li>Monitor for headache</li>
<li>Process samples per protocol</li>
</ol>
<h2>References</h2>
<ol>
<li><strong>Biomarker Guidelines</strong>: Blennow, K., et al. (2015). &quot;CSF biomarkers in AD.&quot; <em>Alzheimer's &amp; Dementia</em>.</li>
<li><strong>Pre-analytical Factors</strong>: Vanderstichele, H., et al. (2012). &quot;Standardization of CSF Aβ42 measurements.&quot; <em>Alzheimer's &amp; Dementia</em>.</li>
<li><strong>ATN Framework</strong>: Jack, C.R., et al. (2018). &quot;NIA-AA Research Framework.&quot; <em>Alzheimer's &amp; Dementia</em>.</li>
</ol>

{% endraw %}